Single-Center Experience With Epigenetic Treatment for Juvenile Myelomonocytic Leukemia

Conclusion: Our data show that AZA monotherapy is safe and effective in controlling disease both in upfront and relapsed patients in order to proceed to HSCT.
Source: Frontiers in Oncology - Category: Cancer & Oncology Source Type: research